Drugs designed to act against individual molecular targets cannot usually combat multigenic
diseases such as cancer, or diseases that affect multiple tissues or cell types such as …

The biological redundancies in molecular networks of complex diseases limit the efficacy of
many single drug therapies. Combination therapeutics, as a common therapeutic method …

The majority of diseases are associated with alterations in multiple molecular pathways and
complex interactions at the cellular and organ levels. Single-target monotherapies therefore …

Polypharmacology offers a model for the way drug discovery must evolve to develop
therapies most suited to treating currently incurable diseases. It is driven by a worldwide …

Cancer therapies that target key molecules have not fulfilled expected promises for most
common malignancies. Major challenges include the incomplete understanding and …

Understanding the molecular mechanisms underlying synergistic, potentiative and
antagonistic effects of drug combinations could facilitate the discovery of novel efficacious …

At present, the legendary magic bullet, ie, a drug with high potency and selectivity toward a
specific biological target, shares the spotlight with an emerging and alternative …

For much of the past century, drug discovery relied largely on the use of animal models of
disease as the first-line screens for testing the compounds produced by medicinal chemists …

Modulating multiple protein targets simultaneously can be beneficial for treating complex
diseases. The redundancy that exists within biological networks means that modulating …

Due to the complexity of multifactorial diseases, single-target drugs do not always exhibit
satisfactory efficacy. Recently, increasing evidence indicates that simultaneous modulation …